We develop an exiting technology based on empirical evidence, inspired by nature and we would like the world to know about this. Here is an overview of our communication to the world.
SurvivX CEO invited as keynote speaker at Hollandbio Event
To celebrate the arrival of a new 'Customized Health' program from Hollandbio, and event has organised called "Biotech Wednesday" on November 15. Our CEO, Remko van Leeuwen has been invited as keynote…
Lees verder
Lees verder
SurvivX highlighted during summit with Netherlands PM Mark Rutte in India
Our novel sepsis treatment, called SUR-101, which we develop collaboratively by the Centre for Cellular and Molecular Platforms (C-CAMP) and the Institute of Life Sciences in India, was official licensed to Dutch…
Lees verder
Lees verder
Financiering voor SurvivX: verder onderzoek naar medicijn voor de behandeling van sepsis
Met een investering vanuit het Vroegefasefinanciering Gelderland kan het Nijmeegse SurvivX verder met de ontwikkeling van een medicijn tegen sepsis.
Lees verder
Lees verder
Therapeutic role of Filarial HSP70 in murine models of polymicrobial sepsis and H1N1 Influenza
Paresh Patel, Shilpa Siddappa, Balachandran Ravindran, and Taslimarif Saiyed.
Lees verder
Lees verder
